Notifications

Home

Stocks
- Stock Screener
- Market Movers
- Insider Trades
- Upcoming Earnings
- Upcoming Dividends
Options
- Unusual Options Activity
- Implied Volatility Rank
- Volatility %Change
News
Upcoming IPOs

Eledon Pharmaceuticals Inc (ELDN)

$3.94 +0.06 (1.55%)

Overview
Financial
Short Interest
Institutional Holdings
Dividends
Charts

Market Cap	299.49M
Revenue (ttm)	0.00
Net Income (ttm)	-45.62M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,316,500
Avg Vol	1,476,830
Day's Range	N/A - N/A
Shares Out	77.19M
Stochastic %K	43%
Beta	0.94
Analysts	Strong Sell
Price Target	$8.60

Company Profile

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for th...

Industry: Biotechnology

Sector: Healthcare

Phone: 949 238 8090

Website: eledon.com

Address:

19800 MacArthur Boulevard, Suite 250, Irvine, United States

red1 Jul. 1 at 12:16 AM

$ELDN if we close above $4 burst trough $4.16 breakout to $7 easy

0 · Reply

Veraton Jun. 30 at 11:49 PM

$ELDN it's going to be wild!!! MASSIVE 🐂

0 · Reply

Crypto_Cartel Jun. 30 at 9:59 PM

$ELDN Shorts “it’s gonna be bad myNi**as”

1 · Reply

red1 Jun. 30 at 6:37 PM

$ELDN a handful of ppl shorting, covering, shorting again

0 · Reply

Ontherag Jun. 30 at 6:04 PM

$ELDN We are right there for blast off

1 · Reply

HouseDR Jun. 30 at 5:54 PM

$ELDN $4 needs to go 😃🙌

0 · Reply

Veraton Jun. 30 at 5:35 PM

$ELDN 😂😂😂

0 · Reply

Penny_stock_Raid_Boss Jun. 30 at 5:33 PM

$ELDN ready for the daily 4 dollar beatdown.

1 · Reply

Veraton Jun. 30 at 5:03 PM

$ELDN Believe in the process!!! Rocket 🚀 Massive 🐂

0 · Reply

Penny_stock_Raid_Boss Jun. 30 at 3:44 PM

$ELDN $NTRA current price 2.45? Wtf drunk bot is drunk.

0 · Reply

Natera, Eledon announce strategic partnership

NTRA

Jun 25, 2026, 7:00 AM EDT - 5 days ago

Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial

NTRA

Jun 22, 2026, 8:00 AM EDT - 8 days ago

Eledon Pharmaceuticals Transcript: Study result

Jun 22, 2026, 8:00 AM EDT - 8 days ago

Eledon Pharmaceuticals Press release: Study result

Jun 22, 2026, 8:00 AM EDT - 8 days ago

Eledon Pharmaceuticals Slides: Study result

2026-06-22T11:41:52.000Z - 8 days ago

Eledon Pharmaceuticals announces new long-term data from BESTOW program

Jun 22, 2026, 7:00 AM EDT - 8 days ago

Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared with Tacrolimus

2026-06-08T11:17:05.000Z - 22 days ago

Eledon Pharmaceuticals announces updated results from tegoprubart trial

Jun 8, 2026, 7:00 AM EDT - 22 days ago

Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine

Jun 4, 2026, 4:31 PM EDT - 26 days ago

Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions

May 20, 2026, 4:05 PM EDT - 5 weeks ago

Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress

2026-05-13T21:28:34.000Z - 6 weeks ago

Eledon Pharmaceuticals reports Q1 EPS (33c), consensus (23c)

May 13, 2026, 4:05 PM EDT - 6 weeks ago

Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights

May 13, 2026, 4:00 PM EDT - 6 weeks ago

Eledon Pharmaceuticals Earnings release: Q1 2026

May 13, 2026, 4:00 PM EDT - 6 weeks ago

Eledon Pharmaceuticals Quarterly report: Q1 2026

2026-05-01T20:15:19.000Z - 2 months ago

Eledon Pharmaceuticals files $500M mixed securities shelf

May 1, 2026, 8:00 AM EDT - 2 months ago

Eledon Pharmaceuticals Registration statement: Registration filing

Apr 30, 2026, 8:00 AM EDT - 2 months ago

Eledon Pharmaceuticals Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 2 months ago

Eledon Pharmaceuticals Proxy statement: Proxy filing

Apr 21, 2026, 8:00 AM EDT - 2 months ago

Eledon Pharmaceuticals Proxy statement: Proxy filing

2026-04-20T11:43:42.000Z - 2 months ago

NewcelX announces release of updated presentation on Type 1 Diabetes program

NCEL

Mar 19, 2026, 5:10 PM EDT - 3 months ago

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results

Mar 19, 2026, 4:00 PM EDT - 3 months ago

Eledon Pharmaceuticals Annual report: Q4 2025

Mar 19, 2026, 4:00 PM EDT - 3 months ago

Eledon Pharmaceuticals Earnings release: Q4 2025

2026-03-16T11:30:46.000Z - 3 months ago

Eledon announces updated data from islet transplant trial of tegoprubart

Mar 11, 2026, 1:40 PM EDT - 3 months ago

Eledon Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026

2026-03-10T11:16:45.000Z - 4 months ago

Eledon Pharmaceuticals announces U.S. FDA granted ODD to tegoprubart

Mar 10, 2026, 7:00 AM EDT - 4 months ago

Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation

2026-03-09T11:12:39.000Z - 4 months ago

NewcelX announces research agreement with Eledon Pharmaceuticals

NCEL

Mar 9, 2026, 7:00 AM EDT - 4 months ago

NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes

NCEL

Mar 4, 2026, 4:05 PM EST - 4 months ago

Eledon Pharmaceuticals to Participate in Leerink Partners 2026 Global Healthcare Conference

Feb 12, 2026, 10:00 AM EST - 4 months ago

Eledon Pharmaceuticals Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 5, 2026, 4:10 PM EST - 5 months ago

Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

2026-01-23T12:05:49.000Z - 5 months ago

Eledon Pharmaceuticals presents long-term Phase 1b data for tegoprubart

Jan 23, 2026, 7:00 AM EST - 5 months ago

Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium

Jan 8, 2026, 4:05 PM EST - 6 months ago

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook

Dec 4, 2025, 8:50 AM EST - 7 months ago

Eledon Pharmaceuticals Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 1, 2025, 7:00 AM EST - 7 months ago

Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference

2025-11-18T21:15:53.000Z - 8 months ago

Eledon Pharmaceuticals reports preliminary tegoprubart trial results

Nov 18, 2025, 4:05 PM EST - 8 months ago

Eledon Reports Preliminary Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart as the Core Immunosuppressant Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine

2025-11-18T11:35:08.000Z - 8 months ago

Eledon Pharmaceuticals price target lowered to $8 from $9 at Guggenheim

2025-11-14T22:05:10.000Z - 8 months ago

Eledon Pharmaceuticals reports Q3 EPS (21c), consensus (25c)

Nov 14, 2025, 5:00 PM EST - 8 months ago

Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results

Nov 14, 2025, 4:00 PM EST - 8 months ago

Eledon Pharmaceuticals Earnings release: Q3 2025

Nov 14, 2025, 4:00 PM EST - 8 months ago

Eledon Pharmaceuticals Quarterly report: Q3 2025

Nov 12, 2025, 10:30 AM EST - 8 months ago

Eledon Pharmaceuticals Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

2025-11-12T13:00:22.000Z - 8 months ago

Eledon prices 15.15M shares at $1.65 in underwritten public offering

Nov 12, 2025, 7:56 AM EST - 8 months ago

Eledon Pharmaceuticals Announces Pricing of $50 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants

2025-11-11T22:30:20.000Z - 8 months ago

Eledon Pharmaceuticals announces common stock, warrant offering, no amount given

Nov 11, 2025, 5:26 PM EST - 8 months ago

Eledon Pharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Nov 7, 2025, 8:00 AM EST - 8 months ago

Eledon Pharmaceuticals Transcript: Study Result

Nov 7, 2025, 8:00 AM EST - 8 months ago

Eledon Pharmaceuticals Press release: Study Result

Nov 7, 2025, 8:00 AM EST - 8 months ago

Eledon Pharmaceuticals Slides: Study Result

Nov 6, 2025, 6:30 PM EST - 8 months ago

Eledon Presents Phase 2 BESTOW Trial Results for Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology's Kidney Week 2025 Annual Meeting

Nov 5, 2025, 7:00 AM EST - 8 months ago

Eledon Pharmaceuticals to Present at Guggenheim Second Annual Healthcare Innovation Conference

Oct 17, 2025, 7:00 AM EDT - 9 months ago

Eledon Pharmaceuticals to Present Results from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology Kidney Week 2025 Annual Meeting

Sep 24, 2025, 4:05 PM EDT - 9 months ago

Eledon Pharmaceuticals to Present at the 18th Congress of the International Xenotransplantation Association

Sep 5, 2025, 9:10 AM EDT - 10 months ago

Eledon Pharmaceuticals Transcript: Cantor Global Healthcare Conference 2025

Aug 29, 2025, 7:00 AM EDT - 10 months ago

Eledon Pharmaceuticals to Participate in Cantor Global Healthcare Conference 2025

Aug 14, 2025, 4:20 PM EDT - 11 months ago

Eledon Pharmaceuticals Reports Second Quarter 2025 Operating and Financial Results

Aug 14, 2025, 4:00 PM EDT - 11 months ago

Eledon Pharmaceuticals Quarterly report: Q2 2025

Aug 14, 2025, 4:00 PM EDT - 11 months ago

Eledon Pharmaceuticals Earnings release: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 11 months ago

Eledon Pharmaceuticals Transcript: Study Update

Aug 6, 2025, 4:30 PM EDT - 11 months ago

Eledon Pharmaceuticals Press release: Study Update

Aug 6, 2025, 4:30 PM EDT - 11 months ago

Eledon Pharmaceuticals Slides: Study Update

Aug 6, 2025, 4:01 PM EDT - 11 months ago

Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

Jul 30, 2025, 4:05 PM EDT - 11 months ago

Eledon Pharmaceuticals to Host a Conference Call to Discuss Updated Data from the Ongoing Phase 1b Trial of Tegoprubart in Kidney Transplantation Being Presented at the World Transplant Congress 2025

Jul 17, 2025, 4:01 PM EDT - 1 year ago

Updated Data from Eledon Pharmaceuticals' Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation to be Presented at the World Transplant Congress 2025

Jul 9, 2025, 8:30 AM EDT - 1 year ago

Eledon Pharmaceuticals Transcript: R&D Day 2025

Jul 9, 2025, 8:30 AM EDT - 1 year ago

Eledon Pharmaceuticals Slides: FY 2025

Jun 25, 2025, 4:01 PM EDT - 1 year ago

Eledon Pharmaceuticals to Host R&D Day on July 9, 2025 in New York City

May 14, 2025, 4:01 PM EDT - 1 year ago

Eledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial Results

May 14, 2025, 12:00 AM EDT - 1 year ago

Eledon Pharmaceuticals Quarterly report: Q1 2025

May 14, 2025, 12:00 AM EDT - 1 year ago

Eledon Pharmaceuticals Earnings release: Q1 2025

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Eledon Pharmaceuticals Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Eledon Pharmaceuticals Proxy statement: Proxy Filing

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Eledon Pharmaceuticals Proxy statement: Proxy Filing

Apr 1, 2025, 7:00 AM EDT - 1 year ago

Eledon Pharmaceuticals Slides: Corporate Presentation

Mar 20, 2025, 4:01 PM EDT - 1 year ago

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results

Mar 20, 2025, 4:00 PM EDT - 1 year ago

Eledon Pharmaceuticals Annual report: Q4 2024

Mar 20, 2025, 4:00 PM EDT - 1 year ago

Eledon Pharmaceuticals Earnings release: Q4 2024

Mar 11, 2025, 2:20 PM EDT - 1 year ago

Eledon Pharmaceuticals Transcript: Leerink’s Global Healthcare Conference 2025

Mar 4, 2025, 4:05 PM EST - 1 year ago

Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference

Feb 7, 2025, 10:00 AM EST - 1 year ago

Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human

Feb 5, 2025, 1:00 PM EST - 1 year ago

Eledon Pharmaceuticals Transcript: Guggenheim SMID Cap Biotech Conference

Jan 29, 2025, 4:05 PM EST - 1 year ago

Eledon Pharmaceuticals to Participate in Guggenheim Securities SMID Cap Biotech Conference

Jan 13, 2025, 7:00 AM EST - 1 year ago

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook

Nov 13, 2024, 1:30 PM EST - 1 year ago

Eledon Pharmaceuticals Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Nov 12, 2024, 4:01 PM EST - 1 year ago

Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results

Nov 12, 2024, 4:00 PM EST - 1 year ago

Eledon Pharmaceuticals Quarterly report: Q3 2024

Nov 12, 2024, 4:00 PM EST - 1 year ago

Eledon Pharmaceuticals Earnings release: Q3 2024

Oct 29, 2024, 7:46 AM EDT - 1 year ago

Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Oct 29, 2024, 7:45 AM EDT - 1 year ago

Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine

Sep 20, 2024, 8:00 AM EDT - 1 year ago

Eledon Pharmaceuticals Registration statement: Registration Filing

Sep 11, 2024, 4:05 PM EDT - 1 year ago

Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference

Sep 4, 2024, 7:00 AM EDT - 1 year ago

Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients

Aug 14, 2024, 5:21 PM EDT - 2 years ago

Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results

Aug 14, 2024, 3:00 AM EDT - 2 years ago

Eledon Pharmaceuticals Quarterly report: Q2 2024

Aug 14, 2024, 3:00 AM EDT - 2 years ago

Eledon Pharmaceuticals Earnings release: Q2 2024

Jul 29, 2024, 7:00 AM EDT - 2 years ago

Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection

Jul 2, 2024, 4:05 PM EDT - 2 years ago

Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism

May 30, 2024, 8:00 AM EDT - 2 years ago

Eledon Pharmaceuticals Proxy statement: Proxy Filing

May 30, 2024, 8:00 AM EDT - 2 years ago

Eledon Pharmaceuticals Proxy statement: Proxy Filing

May 24, 2024, 8:00 AM EDT - 2 years ago

Eledon Pharmaceuticals Registration statement: Registration Filing

May 9, 2024, 4:00 PM EDT - 2 years ago

Eledon Pharmaceuticals Quarterly report: Q1 2024

May 9, 2024, 4:00 PM EDT - 2 years ago

Eledon Pharmaceuticals Earnings release: Q1 2024

May 9, 2024, 7:30 AM EDT - 2 years ago

Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results

May 9, 2024, 7:00 AM EDT - 2 years ago

Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress

May 7, 2024, 7:05 AM EDT - 2 years ago

Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection

Mar 28, 2024, 4:01 PM EDT - 2 years ago

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results

Mar 28, 2024, 4:00 PM EDT - 2 years ago

Eledon Pharmaceuticals Annual report: Q4 2023

Mar 28, 2024, 4:00 PM EDT - 2 years ago

Eledon Pharmaceuticals Earnings release: Q4 2023

Mar 25, 2024, 4:56 PM EDT - 2 years ago

Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection

Mar 21, 2024, 10:31 AM EDT - 2 years ago

Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human

Feb 13, 2024, 7:01 PM EST - 2 years ago

Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 4, 2024, 4:40 PM EST - 2 years ago

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook

red1 Jul. 1 at 12:16 AM

$ELDN if we close above $4 burst trough $4.16 breakout to $7 easy

0 · Reply

Veraton Jun. 30 at 11:49 PM

$ELDN it's going to be wild!!! MASSIVE 🐂

0 · Reply

Crypto_Cartel Jun. 30 at 9:59 PM

$ELDN Shorts “it’s gonna be bad myNi**as”

1 · Reply

red1 Jun. 30 at 6:37 PM

$ELDN a handful of ppl shorting, covering, shorting again

0 · Reply

Ontherag Jun. 30 at 6:04 PM

$ELDN We are right there for blast off

1 · Reply

HouseDR Jun. 30 at 5:54 PM

$ELDN $4 needs to go 😃🙌

0 · Reply

Veraton Jun. 30 at 5:35 PM

$ELDN 😂😂😂

0 · Reply

Penny_stock_Raid_Boss Jun. 30 at 5:33 PM

$ELDN ready for the daily 4 dollar beatdown.

1 · Reply

Veraton Jun. 30 at 5:03 PM

$ELDN Believe in the process!!! Rocket 🚀 Massive 🐂

0 · Reply

Penny_stock_Raid_Boss Jun. 30 at 3:44 PM

$ELDN $NTRA current price 2.45? Wtf drunk bot is drunk.

0 · Reply

BarbaraSmith247 Jun. 30 at 1:43 PM

$ELDN current price 2.45. The announcement of a partnership with $NTRA for the use of the Prospera test in the upcoming Phase 3 trial for tegoprubart provides a clear data-driven roadmap. Market focus remains on the scale of global patient enrollment starting later this year. Balance sheet and cash runway remain the primary variables for long-term holders.

0 · Reply

Penny_stock_Raid_Boss Jun. 29 at 8:56 PM

$ELDN yo guys i cannot say who told me, but i heard ther's a buy signal.

2 · Reply

Veraton Jun. 29 at 2:47 PM

$ELDN They are buying a shit hole before closing bell today.... Massive 🐂

0 · Reply

Penki1985 Jun. 29 at 2:00 PM

$ELDN Getting hammered every time it tries to cross the 4$ level.

2 · Reply

sethsethsethseth Jun. 29 at 1:43 PM

$ELDN gooooooooooooooooo

0 · Reply

HouseDR Jun. 29 at 1:38 PM

$ELDN Ready for a breakout

0 · Reply

Veraton Jun. 29 at 12:52 PM

$ELDN

0 · Reply

Veraton Jun. 29 at 12:46 PM

$ELDN

0 · Reply

Veraton Jun. 29 at 12:44 PM

$ELDN

0 · Reply

Crypto_Cartel Jun. 28 at 12:57 AM

$ELDN sounds like @red1 was hacked by a chat gpt bot

2 · Reply

red1 Jun. 27 at 7:35 PM

$ELDN Eledon Pharmaceuticals did trigger a technical buy signal from a pivot bottom point on Thursday, June 25, 2026, following a period of decline that started after its April 20 pivot top. The stock has already responded positively to this signal, closing at $3.78 on Friday, June 26, up 2.33% for the session and extending its multi-day bounce from recent lows.

0 · Reply

Veraton Jun. 27 at 4:13 PM

$ELDN massive But WGAF.....

0 · Reply

1.0.0